The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.
Dell Inc. has extended its partnership with Translational Genomics Research Institute (TGen) to assist reasearchers and physicians expand the impact and reach of precision medicine efforts for pediatric cancer.
Not every cancer is curable. The patient, may sometimes need to “live with it’, as is the case with diabetes or heart diseases. Controlling, rather than curing is the best course ahead for certain types of cancers including ovarian, chronic leukemia, some lymphomas, and metastatic breast and prostate cancers. Controlling cancer implies to limit the spreading. The cancer may shrink, but nevertheless it will be there.